MA50921A - Sels et formes cristallines d'un modulateur allostérique positif du gabaa - Google Patents
Sels et formes cristallines d'un modulateur allostérique positif du gabaaInfo
- Publication number
- MA50921A MA50921A MA050921A MA50921A MA50921A MA 50921 A MA50921 A MA 50921A MA 050921 A MA050921 A MA 050921A MA 50921 A MA50921 A MA 50921A MA 50921 A MA50921 A MA 50921A
- Authority
- MA
- Morocco
- Prior art keywords
- gabaa
- salts
- crystalline forms
- positive allosteric
- allosteric modulator
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725805P | 2018-08-31 | 2018-08-31 | |
| US16/517,369 US10562930B1 (en) | 2018-08-31 | 2019-07-19 | Salts and crystal forms of GABAA positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50921A true MA50921A (fr) | 2020-09-23 |
Family
ID=69528249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050921A MA50921A (fr) | 2018-08-31 | 2019-08-30 | Sels et formes cristallines d'un modulateur allostérique positif du gabaa |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10562930B1 (enExample) |
| EP (2) | EP4458357B1 (enExample) |
| JP (3) | JP7199739B2 (enExample) |
| KR (1) | KR102845326B1 (enExample) |
| CN (2) | CN113473991B (enExample) |
| AU (1) | AU2019333310B8 (enExample) |
| BR (1) | BR112021003727A2 (enExample) |
| CA (1) | CA3111193A1 (enExample) |
| IL (1) | IL281143B2 (enExample) |
| MA (1) | MA50921A (enExample) |
| MX (1) | MX2021002382A (enExample) |
| TW (2) | TWI823999B (enExample) |
| WO (1) | WO2020047434A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY190408A (en) * | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| JP2022514510A (ja) * | 2018-12-14 | 2022-02-14 | プラクシス プレシジョン メディスンズ，インコーポレイテッド | うつ病の治療方法 |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| WO2022006541A1 (en) * | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Methods for the treatment of adjustment disorder |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| WO2022178000A1 (en) * | 2021-02-18 | 2022-08-25 | Praxis Precision Medicines, Inc. | Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof |
| US20240207366A1 (en) | 2021-04-27 | 2024-06-27 | Kyungpook National University Industry-Academic Cooperation Foundation | Food composition and pharmaceutical composition for preventing or alleviating sarcopenia, containing low-molecular-weight collagen as active ingredient |
| WO2023159035A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| US20250170148A1 (en) * | 2022-02-28 | 2025-05-29 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
| EP4514357A4 (en) * | 2022-04-26 | 2026-04-29 | Praxis Prec Medicines Inc | METHODS OF TREATING NEUROLOGICAL DISORDERS |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4008024B2 (ja) * | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| PT837874E (pt) | 1995-06-06 | 2005-03-31 | Euro Celtique Sa | Esteroides neuroactivos da serie androstano e pregnano |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| UA73736C2 (en) | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| CN1688288A (zh) * | 2002-08-05 | 2005-10-26 | 巴克斯特国际公司 | 具有多晶型控制的亚微米粒度颗粒的制备和新多晶型伊曲康唑 |
| WO2004072079A1 (en) | 2003-02-11 | 2004-08-26 | Pfizer Limited | Hydrated and anhydrous sildenafil hemi-citrate compound |
| WO2005007600A2 (en) | 2003-07-11 | 2005-01-27 | Eisai Co., Ltd. | Novel methods using aminobenzoic acid compounds |
| AU2004265101B2 (en) | 2003-08-14 | 2009-06-11 | F. Hoffmann-La Roche Ag | Gabanergic modulators |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US20060074059A1 (en) | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| DK2168585T3 (da) | 2005-06-09 | 2012-02-27 | Euro Celtique Sa | Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| JP2009530385A (ja) | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| ES2635358T3 (es) * | 2009-04-23 | 2017-10-03 | Theravance Respiratory Company, Llc | Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico |
| WO2011104637A2 (en) * | 2010-02-24 | 2011-09-01 | Ramot At Tel-Aviv University Ltd. | Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same |
| KR20140009244A (ko) * | 2010-11-11 | 2014-01-22 | 애크런 몰레큘스 게엠베하 | 통증 치료용 화합물 및 방법 |
| WO2013006857A1 (en) | 2011-07-07 | 2013-01-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| EP3308785A3 (en) | 2013-07-24 | 2018-07-18 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug |
| KR102516745B1 (ko) * | 2014-08-01 | 2023-03-31 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도 |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| MY190408A (en) * | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| US10420773B2 (en) | 2017-09-26 | 2019-09-24 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with etifoxine |
| SG11202004329TA (en) | 2017-11-10 | 2020-06-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| JP2022514510A (ja) | 2018-12-14 | 2022-02-14 | プラクシス プレシジョン メディスンズ，インコーポレイテッド | うつ病の治療方法 |
| US12325726B2 (en) | 2018-12-17 | 2025-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX2021010744A (es) | 2019-03-04 | 2022-01-18 | Praxis Prec Medicines Inc | Metodos para el tratamiento de la perimenopausia y la menopausia. |
| WO2020185710A1 (en) | 2019-03-08 | 2020-09-17 | Alairion, Inc. | Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor |
| US20220265666A1 (en) | 2019-08-02 | 2022-08-25 | Praxis Precision Medicines, Inc. | Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression |
| AU2020358002A1 (en) | 2019-10-02 | 2022-04-21 | Praxis Precision Medicines, Inc. | Combinations of GABA-A receptor positive allosteric modulators and NMDA antagonists, NMDA negative allosteric modulators or NMDA partial agonists |
| WO2021168106A1 (en) | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| WO2022006541A1 (en) | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Methods for the treatment of adjustment disorder |
| US20230416300A1 (en) | 2020-08-20 | 2023-12-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2022178000A1 (en) | 2021-02-18 | 2022-08-25 | Praxis Precision Medicines, Inc. | Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof |
| CN117715641A (zh) | 2021-04-26 | 2024-03-15 | 普拉西斯精密医药公司 | 用神经活性类固醇进行治疗的方法 |
| WO2023159094A2 (en) | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
| EP4514357A4 (en) | 2022-04-26 | 2026-04-29 | Praxis Prec Medicines Inc | METHODS OF TREATING NEUROLOGICAL DISORDERS |
-
2019
- 2019-07-19 US US16/517,369 patent/US10562930B1/en active Active
- 2019-08-30 EP EP24194131.9A patent/EP4458357B1/en active Active
- 2019-08-30 JP JP2020517339A patent/JP7199739B2/ja active Active
- 2019-08-30 IL IL281143A patent/IL281143B2/en unknown
- 2019-08-30 CN CN201980071246.9A patent/CN113473991B/zh active Active
- 2019-08-30 BR BR112021003727-6A patent/BR112021003727A2/pt unknown
- 2019-08-30 CN CN202511898870.XA patent/CN122103232A/zh active Pending
- 2019-08-30 EP EP19842855.9A patent/EP3710465B1/en active Active
- 2019-08-30 MX MX2021002382A patent/MX2021002382A/es unknown
- 2019-08-30 TW TW108131297A patent/TWI823999B/zh active
- 2019-08-30 KR KR1020217009437A patent/KR102845326B1/ko active Active
- 2019-08-30 AU AU2019333310A patent/AU2019333310B8/en active Active
- 2019-08-30 WO PCT/US2019/049103 patent/WO2020047434A1/en not_active Ceased
- 2019-08-30 CA CA3111193A patent/CA3111193A1/en active Pending
- 2019-08-30 MA MA050921A patent/MA50921A/fr unknown
- 2019-08-30 TW TW112141287A patent/TWI850138B/zh active
- 2019-11-27 US US16/698,057 patent/US10927141B2/en active Active
-
2021
- 2021-01-07 US US17/143,602 patent/US20220024967A1/en not_active Abandoned
-
2022
- 2022-12-14 JP JP2022199092A patent/JP2023036708A/ja active Pending
-
2023
- 2023-12-05 US US18/529,117 patent/US12404297B2/en active Active
-
2024
- 2024-10-03 JP JP2024174009A patent/JP2025020120A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
| EP3870178A4 (en) | Crystalline forms of mnk inhibitors | |
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| IL290106A (en) | Crystalline form of atr inhibitor and use thereof | |
| MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
| EP4178960A4 (en) | SALTS AND FORMS OF A WEE1 INHIBITOR | |
| DK3844407T3 (da) | Sæt af plader med en mekanisk låseanordning | |
| DK4093980T3 (da) | Sæt af plader med en mekanisk låseanordning | |
| EP3807279A4 (en) | PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE | |
| IL281143A (en) | Salts and crystal forms of gabaa positive allosteric modulator | |
| IL287668A (en) | Crystalline forms of a btk inhibitor | |
| EP3353175A4 (en) | SALTS AND SOLID FORMS OF MONOBACTAM ANTIBIOTICS | |
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| EP3681507A4 (en) | URSO ACID MORPHOLINE AND DIETHANOLAMINE SALTS | |
| MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
| IL308750A (en) | Novel salts and crystals | |
| MA53671A (fr) | Formes cristallines d'un agoniste du récepteur farnésoïde x | |
| EP3873463A4 (en) | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | |
| DK3643718T3 (da) | Heterocyklisk forbindelse og anvendelse deraf som positiv allosterisk modulator af den kolinerge muskarin m1-receptor | |
| EP3849964A4 (en) | CRYSTALLINE FORMS OF A QUINAZOLE COMPOUND AND ITS HYDROCHLORIDE SALTS | |
| SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
| EP3672972A4 (en) | SALT OF A COMPOUND AND CRYSTALLINE FORMS OF IT | |
| MA56445A (fr) | Dérivé de tétrahydroisoquinoléine substitué utilisé comme modulateur allostérique positif de d1 | |
| EP3887356C0 (en) | MULTICOMPONENT CRYSTALS OF AN ORALLY AVAILABLE HIF PROLYL HYDROXYLASE INHIBITOR | |
| EP4369934A4 (en) | CRYSTALLINE FORMS OF TROFINETIDE |